

ADNI 3 Partnership

The Alzheimer's Disease Neuroimaging Initiative (ADNI) is conducted by the National Institute on Aging (NIA) in conjunction with other federal agencies and private-sector corporations and not-for-profit organizations. To date, the NIH's largest public-private partnership on brain research, ADNI is a landmark study currently housed at 59 clinical sites in the United States and Canada. It is designed to develop methods, acquire data and form a collaborative network of clinical and imaging sites to facilitate use and evaluation of neuroimaging and other biomarkers in clinical trials aimed at slowing the onset and progression of Alzheimer's disease (AD). ADNI 3 began in 2016 and will continue through 2022.

ADNI3 builds on the efforts of first and second phases of ADNI and seeks to identify the earliest changes in brain structure and function as people transition from normal cognitive aging to mild cognitive aging (MCI) and early AD. In addition to continuing to follow approximately 697 subjects from the first and second phase annually (approximately 295 cognitively normal controls, 274 subjects with MCI, and 128 subjects with dementia diagnosed as AD), ADNI3 proposes to enroll approximately 371 new subjects (approximately 133 cognitively normal controls, 151 subjects with MCI, and 87 subjects with dementia diagnosed as AD), while collecting clinical, cognitive, MRI (structural, diffusion, perfusion, resting state), amyloid PET, FDG PET, cerebrospinal fluid (for A β , tau, phosphotau, and other proteins), and genetic and autopsy data. In addition, the grant proposes to perform longitudinal measurements of brain tau PET on all subjects. Furthermore, the Project will also enhance its current clinical batteries by adding computerized cognitive testing, and a performance-based functional assessment, and its genetics methodology by including a novel systems biology/modeling analysis approach.

ADNI is supported by a partnership of more than 20 private and not-for-profit organizations coordinated by the Foundation for the NIH (FNIH).

WHAT MAKES ADNI UNIQUE FROM OTHER AD STUDIES?

ADNI is the only large multisite observational and longitudinal study of AD featuring: The largest and longest continually monitored AD longitudinal subject pool, with over 15 years of data including:

- Clinical cognitive assessments (including computerized assessments);
- Conventional and advanced MRI;
- Collection of CSF (lumbar puncture);
- Amyloid PET, tau PET, FDG PET;
- Genetic analysis;
- Plasma/serum banking; and
- Open access to all data, without embargo, deposited in the database Laboratory of Neuro Imaging (LONI) <http://www.loni.usc.edu/>

No other study provides this!

HOW IS ADNI 3 DIFFERENT FROM ADNI 1 & 2?

- ADNI 3 distinguishes itself from ADNI 1 & 2 with:
- Annual tau PET imaging
- A "Centiloid" amyloid PET approach
- Improved CSF biomarker methods, including mass spectrometry methods
- Advanced MRI PET scans using "connectome methods"
- Online cognitive testing
- A "Systems biology" or "modeling" analysis approach



Accelerate Cure/Treatments for Alzheimer's Disease



THE THERAPIES TO REMEMBER



Alzheimer's
Drug Discovery
Foundation



GRIFOLS



Global clinical trial solutions. Real-world results.



COGSTATE



THE THERAPEUTICS



DIAMIR



a PerkinElmer company

FUJIFILM Toyama Chemical Co., Ltd.



A Member of the Roche Group



BUILDING INNOVATIVE COLLABORATIONS

WHEN IS ADNI 3 EXPECTED TO START AND CONCLUDE?

September 2016 - August 2022

HOW CAN I BECOME A PARTNER IN ADNI?

FNIH invites you to become a partner in ADNI 3 by providing scientific and financial support to the study. The NIH has invested approximately \$40 million in this initiative over a six-year timeframe. FNIH seeks private sector support totaling \$20 million to fully fund the estimated \$60 million study. Funding partners in ADNI are invited to join the Private Partner Scientific Board (PPSB), where corporations and non-profit patient advocacy organizations work together in a pre-competitive environment to engage in study-related scientific exchanges. Each funding partner is represented by a voting member of the PPSB. Members:

Study data includes:

- MRI and PET images
- Genetics
- Cognitive tests
- CSF
- Blood biomarkers

- Work together in a proven, pre-competitive environment that facilitates intellectual, scientific and data sharing exchanges
- Receive regular updates and status reports on ADNI progress and activities at monthly PPSB teleconferences and biannual PPSB face-to-face meetings
- Have representation on the ADNI Executive Committee through the PPSB Chair
- Interact with key public sector agencies involved in the clinical trial process for AD
- Build relationships through interaction with NIH, FDA, ADNI PI/Core Leaders and industry colleagues
- Participate in industry-initiated Working Groups – Clinical Endpoints, PET imaging endpoints, Biofluid Biomarkers and others that may be established
- Participate in annual ADNI Steering Committee and World-Wide ADNI meetings
- Participate as a liaison between the ADNI PPSB and the ADNI Cores during ADNI Core teleconferences
- Benefit from being part of an established AD collaboration without having to incur the transaction costs needed to create a new consortium for drug discovery and clinical trials
- Receive recognition on select ADNI press releases, electronic and printed materials, in the FNIH annual report and on ADNI and FNIH web sites where appropriate

HOW DO COMPANIES AND ORGANIZATIONS INVEST IN ADNI 3?

Contribution levels are assessed based on organization type and annual world-wide revenue. Commitments are formalized through a Letter of Agreement with the FNIH and payments are made annually. For organizations that join in 2020 the total contribution will be divided into equal installments for the remaining project years (or mutually agreed upon alternative payment schedule).

Total Contribution	Based on World-Wide Revenue
\$3,000,000	\$50 billion revenue/year
\$2,000,000	\$20-50 billion revenue/year
\$1,000,000	\$10-20 billion revenue/year
\$500,000	\$1-10 billion revenue/year
\$250,000	\$500-999 million revenue/year
\$125,000	<\$499 million sales/year
\$50,000	<\$100 million sales/year

WHO DO I CONTACT ABOUT SUPPORTING ADNI 3?

Heidi Blythe, MPA
Development Officer
(301) 443-1744
hblythe@fnih.org

Joseph Menetski, PhD
Associate Vice President
of Research Partnerships
(301) 594-6596
jmenetski@fnih.org

Eline Appelmans M.D., MPH, BMedSci
Scientific Program Manager,
Neuroscience
(301) 827-4817
eappelmans@fnih.org

